Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Assets (2016 - 2025)

Historic Assets for Viking Therapeutics (VKTX) over the last 12 years, with Q3 2025 value amounting to $739.4 million.

  • Viking Therapeutics' Assets fell 2116.17% to $739.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $739.4 million, marking a year-over-year decrease of 2116.17%. This contributed to the annual value of $908.3 million for FY2024, which is 14649.81% up from last year.
  • Latest data reveals that Viking Therapeutics reported Assets of $739.4 million as of Q3 2025, which was down 2116.17% from $827.9 million recorded in Q2 2025.
  • In the past 5 years, Viking Therapeutics' Assets ranged from a high of $967.5 million in Q1 2024 and a low of $150.9 million during Q1 2023
  • Its 5-year average for Assets is $480.7 million, with a median of $368.5 million in 2023.
  • Its Assets has fluctuated over the past 5 years, first plummeted by 2574.51% in 2022, then skyrocketed by 54118.63% in 2024.
  • Quarter analysis of 5 years shows Viking Therapeutics' Assets stood at $210.7 million in 2021, then dropped by 20.0% to $168.5 million in 2022, then surged by 118.65% to $368.5 million in 2023, then surged by 146.5% to $908.3 million in 2024, then decreased by 18.6% to $739.4 million in 2025.
  • Its Assets stands at $739.4 million for Q3 2025, versus $827.9 million for Q2 2025 and $867.0 million for Q1 2025.